RedHill Biopharma (RDHL) Equity Ratio: 2014-2024
Historic Equity Ratio for RedHill Biopharma (RDHL) over the last 11 years, with Dec 2024 value amounting to -0.26.
- RedHill Biopharma's Equity Ratio fell 22.22% to -22.75 in Q2 2025 from the same period last year, while for Jun 2025 it was -22.75, marking a year-over-year decrease of 22.22%. This contributed to the annual value of -0.26 for FY2024, which is 389.11% down from last year.
- Per RedHill Biopharma's latest filing, its Equity Ratio stood at -0.26 for FY2024, which was down 389.11% from 0.09 recorded in FY2023.
- In the past 5 years, RedHill Biopharma's Equity Ratio ranged from a high of 0.09 in FY2023 and a low of -0.30 during FY2022.
- For the 3-year period, RedHill Biopharma's Equity Ratio averaged around -0.16, with its median value being -0.26 (2024).
- In the last 5 years, RedHill Biopharma's Equity Ratio slumped by 721.96% in 2022 and then spiked by 129.47% in 2023.
- Yearly analysis of 5 years shows RedHill Biopharma's Equity Ratio stood at 0.08 in 2020, then slumped by 36.32% to 0.05 in 2021, then tumbled by 721.96% to -0.30 in 2022, then spiked by 129.47% to 0.09 in 2023, then slumped by 389.11% to -0.26 in 2024.